Nurix bexobrutideg shows 80.9% ORR in CLL, 84.2% in WM; pivotal trials on track for 2025

Nurix Therapeutics, Inc.

ORR 80.9% in CLL/SLL (n=47 evaluable); median time to first response 1.9 months; one complete response after >2 years.
ORR 84.2% in WM (n=19 evaluable); included 10.5% VGPR, 57.9% PR; IgM reductions >90% in three patients.
Well tolerated across 50-600 mg doses; common AEs low-grade purpura/contusion (45.8%), neutropenia (29.2%); no new atrial fibrillation.
Patients heavily pretreated: median 4 prior lines, 97.9% prior BTKi, 83.3% prior BCL2i; responses seen regardless of baseline mutations or CNS involvement.
Nurix on track to initiate pivotal trials of bexobrutideg in 2025.

item 7.01item 8.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.